Q-omics provides the consensus-scored ITPRID1 profile across patient tissues and cancer cell-line models. ITPRID1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ITPRID1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ITPRID1 RNA expression shows 11,151 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, COAD, and TGCT as cancer lineages where ITPRID1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITPRID1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITPRID1 survival associations across molecular data types. ITPRID1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITPRID1 RNA expression–survival associations across cancer types. High ITPRID1 expression shows unfavorable associations in LGG and COAD, but favorable associations in UCEC, ESCA, LIHC and BRCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ITPRID1 RNA expression.
This table summarizes ITPRID1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ITPRID1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITPRID1 shows lower tumor expression in COAD, HNSC and BRCA and higher tumor expression in LUAD, UCEC and KICH. The COAD box plot shows higher ITPRID1 RNA expression in normal versus tumor tissue (log2 FC = −0.418, t-test p < 0.001).
This table shows molecular features associated with ITPRID1 in patient tissues and cancer cell lines. In patient samples, ITPRID1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ITPRID1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
